Selinexor

證據等級: L5

預測適應症: 1 個

Selinexor: Original Indication Not on File — Predicted Application in Drug-Induced Osteoporosis

One-Sentence Summary

The current evidence pack does not include Selinexor's original approved indication or mechanism of action — both are marked as data gaps. The TxGNN model predicts a possible association with Drug-Induced Osteoporosis, but this prediction is currently supported by 0 clinical trials and 0 publications, making it a model-only hypothesis at this stage.

Quick Overview

Item	Content
Original Indication	Not available — no approved indications on file for this drug
Predicted New Indication	Drug-Induced Osteoporosis
TxGNN Prediction Score	99.22%
Evidence Level	L5
Finland Market Status	Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available for Selinexor in this evidence pack, and no original indication is on record to compare against. Based on the limited mechanistic information captured in the prediction rationale, Selinexor is an XPO1 (exportin-1 / nuclear export protein) inhibitor. Clinically, this drug class is associated with systemic metabolic effects such as weight loss, fatigue, nausea, and hyponatremia.

The link to drug-induced osteoporosis is speculative: it is theorized that long-term use could indirectly affect bone metabolism pathways (e.g., through glucocorticoid-like effects or nutritional decline), but this is an inference, not an established mechanistic connection. No direct pharmacological link between XPO1 inhibition and bone metabolism is documented in this evidence pack. The TxGNN score of 99.22% reflects model confidence only and does not by itself constitute mechanistic or clinical evidence.

Clinical Trial Evidence

Currently no related clinical trials registered

Literature Evidence

Currently no related literature available

Finland Market Information

Selinexor is not currently marketed in Finland, and no marketing authorizations are on record.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: This prediction is currently supported only by the TxGNN model score (Evidence Level L5), with no clinical trials, literature, mechanism of action data, or Finland market presence to corroborate it. There is insufficient evidence to advance this candidate at this time.

To proceed, the following is needed:

Selinexor's original approved indication(s) and confirmed mechanism of action (MOA)
TFDA/Fimea package insert data (warnings, contraindications, drug interactions) — currently a blocking data gap
Clinical trial or literature evidence directly linking Selinexor (or its drug class) to bone metabolism/osteoporosis
Reassessment of mechanistic plausibility once MOA data is obtained
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.